MENU
+Compare
RARE
Stock ticker: NASDAQ
AS OF
Oct 17 closing price
Price
$32.63
Change
-$1.34 (-3.94%)
Capitalization
3.15B

RARE Ultragenyx Pharmaceutical Forecast, Technical & Fundamental Analysis

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company... Show more

Industry: #Biotechnology
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for RARE with price predictions
Oct 17, 2025

Momentum Indicator for RARE turns positive, indicating new upward trend

RARE saw its Momentum Indicator move above the 0 level on September 29, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for RARE just turned positive on September 30, 2025. Looking at past instances where RARE's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

RARE moved above its 50-day moving average on September 26, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RARE crossed bullishly above the 50-day moving average on October 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RARE advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for RARE moved out of overbought territory on October 17, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RARE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RARE broke above its upper Bollinger Band on October 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RARE entered a downward trend on October 06, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RARE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.790) is normal, around the industry mean (24.226). P/E Ratio (0.000) is within average values for comparable stocks, (54.529). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (5.163) is also within normal values, averaging (349.660).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

RARE is expected to report earnings to rise 5.13% to -123 cents per share on November 04

Ultragenyx Pharmaceutical RARE Stock Earnings Reports
Q3'25
Est.
$-1.23
Q2'25
Beat
by $0.13
Q1'25
Missed
by $0.01
Q4'24
Missed
by $0.05
Q3'24
Beat
by $0.08
The last earnings report on August 05 showed earnings per share of -116 cents, beating the estimate of -129 cents. With 1.24M shares outstanding, the current market capitalization sits at 3.15B.
A.I. Advisor
published General Information

General Information

a developer of therapeutics for rare diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
60 Leveroni Court
Phone
+1 415 483-8800
Employees
1276
Web
https://www.ultragenyx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SBSIX14.39-0.01
-0.07%
Segall Bryant & Hamill Intl Sm Cp Ins
BSGLX40.05-0.07
-0.17%
Baillie Gifford Long Term Global Gr I
JACCX42.10-0.18
-0.43%
Janus Henderson Forty C
JGSVX23.44-0.11
-0.47%
JPMorgan Small Cap Growth R5
KINAX96.74-1.06
-1.08%
Kinetics Internet Adv A

RARE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been closely correlated with MREO. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-3.93%
MREO - RARE
71%
Closely correlated
+2.50%
NRIX - RARE
49%
Loosely correlated
-1.89%
IONS - RARE
48%
Loosely correlated
+0.03%
NUVL - RARE
47%
Loosely correlated
+2.32%
TRDA - RARE
47%
Loosely correlated
-5.02%
More

Groups containing RARE

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-3.93%
RARE
(2 stocks)
100%
Closely correlated
-0.71%